Skip to main content

Advertisement

SpringerLink
Log in

Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Objective

To explore the association of functional single-nucleotide polymorphisms (SNPs) of CD133 with the risk of lung cancer.

Methods

We conducted a hospital-based, case–control study of 1017 lung cancer patients and 1035 cancer-free controls frequency-matched by age and sex. Four functional CD133 SNPs (rs2240688 A > C, rs10022537 T > A, rs7686732 C > G, and rs3130 C > T) were selected and genotyped. Unconditional univariate and multivariate logistic regression analyses were carried out to evaluate the associations of genotypes of CD133 SNPs with lung cancer risk.

Results

Compared with rs2240688 AA genotype, the variant AC/CC genotypes were associated with a statistically increased risk of lung cancer under a recessive model (adjusted odds ratio 1.19; 95 % confidence interval 1.01–1.42). The risk remained in patients with other histology types, but not with adenocarcinoma and squamous cell cancers.

Conclusions

These findings suggest that SNP rs2240688 A > C of CD133 may be a potential biomarker for genetic susceptibility to lung cancer, but require further research with larger populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SNPs:

Single-nucleotide polymorphisms

CSCs:

Cancer stem cells

TFBS:

Transcription factor-binding site

UTR:

Untranslated region

PCR:

Polymerase chain reaction

OR:

Odds ratio

CI:

Confidence intervals

References

  1. Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19(8):1893–1907. doi:10.1158/1055-9965.EPI-10-0437

    Article  Google Scholar 

  2. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262

    Article  PubMed  Google Scholar 

  3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138

    Article  PubMed  Google Scholar 

  4. Spitz MR, Hong WK, Amos CI et al (2007) A risk model for prediction of lung cancer. J Natl Cancer Inst 99(9):715–726. doi:10.1093/jnci/djk153

    Article  PubMed  Google Scholar 

  5. Thun M, Peto R, Boreham J et al (2012) Stages of the cigarette epidemic on entering its second century. Tob Control 21(2):96–101. doi:10.1136/tobaccocontrol-2011-050294

    Article  PubMed  Google Scholar 

  6. Kim CF, Dirks PB (2008) Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell 3(2):147–150. doi:10.1016/j.stem.2008.07.012

    Article  CAS  PubMed  Google Scholar 

  7. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768. doi:10.1038/nrc2499

    Article  CAS  PubMed  Google Scholar 

  8. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112(13):4793–4807. doi:10.1182/blood-2008-08-077941

    Article  CAS  PubMed  Google Scholar 

  9. Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12):5002–5012

    CAS  PubMed  Google Scholar 

  10. Ferrandina G, Martinelli E, Petrillo M et al (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9:221. doi:10.1186/1471-2407-9-221

    Article  PubMed  PubMed Central  Google Scholar 

  11. Abols A, Ducena K, Zayakin P et al (2014) Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomark 14(5):361–369. doi:10.3233/CBM-140413

    CAS  PubMed  Google Scholar 

  12. Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106(38):16281–16286. doi:10.1073/pnas.0905653106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li Z (2013) CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2(1):17. doi:10.1186/2162-3619-2-17

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hu N, Wang C, Ng D et al (2009) Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. Cancer Res 69(14):5908–5917. doi:10.1158/0008-5472.CAN-08-4622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chung CC, Chanock SJ (2011) Current status of genome-wide association studies in cancer. Hum Genet 130(1):59–78. doi:10.1007/s00439-011-1030-9

    Article  PubMed  Google Scholar 

  16. Pohl A, El-Khoueiry A, Yang D et al (2013) Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 13(2):173–180. doi:10.1038/tpj.2011.61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4(1):32–42

    PubMed  PubMed Central  Google Scholar 

  18. Cheng M, Yang L, Yang R et al (2013) A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis 34(10):2292–2299. doi:10.1093/carcin/bgt181

    Article  CAS  PubMed  Google Scholar 

  19. Wang Q, Liu H, Xiong H et al (2015) Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog 54(6):449–458. doi:10.1002/mc.22113

    Article  CAS  PubMed  Google Scholar 

  20. Okudela K, Woo T, Mitsui H et al (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma—their prognostic significance. Pathol Int 62(12):792–801. doi:10.1111/pin.12019

    Article  CAS  PubMed  Google Scholar 

  21. Corbeil D, Roper K, Fargeas CA et al (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2(2):82–91

    Article  CAS  PubMed  Google Scholar 

  22. Yu X, Lin Y, Yan X et al (2011) CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep 7(4):253–259. doi:10.1007/s11888-011-0106-1

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hu Z, Wu C, Shi Y et al (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43(8):792–796. doi:10.1038/ng.875

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Henan Provincial Science and Technology Department Grant (201201023). We thank Hai-Bo Wang for technical support in statistical analysis.

Author Contributions

Authors Qing-Feng Liu, Zhi-Fei Zhang, and Yi He conceived and designed the experiments. Guang-Jie Hou and Guang-Yu Yang performed the experiments. Qing-Feng Liu and Guang-Yu Yang analyzed the data. Qing-Feng Liu, Zhi-Fei Zhang, and Yi He contributed to the writing of the manuscript. All authors contributed to and have approved the final manuscript.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Henan Provincial People’s Hospital (Zhengzhou University People’s Hospital), 7 Weiwu Street, Zhengzhou, 450003, Henan, People’s Republic of China

    Qing-Feng Liu, Zhi-Fei Zhang, Guang-Jie Hou, Guang-Yu Yang & Yi He

Authors
  1. Qing-Feng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhi-Fei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang-Jie Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guang-Yu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi He.

Ethics declarations

Conflict of interest

All the authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, QF., Zhang, ZF., Hou, GJ. et al. Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population. Lung 194, 393–400 (2016). https://doi.org/10.1007/s00408-016-9876-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-016-9876-1

Keywords

Search

Navigation